Form 8-K Dianthus Therapeutics, For: Mar 11
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Stifel Reiterates Buy Rating on Dianthus Therapeutics (DNTH)
March 12, 2025 7:39 AM EDTStifel analyst Alex Thompson reiterated a Buy rating and $52.00 price target on Dianthus Therapeutics (NASDAQ: DNTH)
The analyst comments "We are reiterating our Buy Rating on DNTH following their 4Q24 update. DNTH remains one of our favorite ideas for 2025 based on our broader view... More
